CN114680215B - 作为有效成分包含发酵熟成诺丽、椰子糖或黑砂糖的运动执行能力及疲劳恢复增进用组合物 - Google Patents
作为有效成分包含发酵熟成诺丽、椰子糖或黑砂糖的运动执行能力及疲劳恢复增进用组合物 Download PDFInfo
- Publication number
- CN114680215B CN114680215B CN202111627646.9A CN202111627646A CN114680215B CN 114680215 B CN114680215 B CN 114680215B CN 202111627646 A CN202111627646 A CN 202111627646A CN 114680215 B CN114680215 B CN 114680215B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- noni
- fermented
- sugar
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000000346 sugar Nutrition 0.000 title claims abstract description 120
- 244000131360 Morinda citrifolia Species 0.000 title claims abstract description 89
- 235000017524 noni Nutrition 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 244000060011 Cocos nucifera Species 0.000 title claims abstract description 70
- 235000013162 Cocos nucifera Nutrition 0.000 title claims abstract description 70
- 238000011084 recovery Methods 0.000 title claims abstract description 31
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 235000009508 confectionery Nutrition 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 241000186660 Lactobacillus Species 0.000 claims description 59
- 229940039696 lactobacillus Drugs 0.000 claims description 59
- 235000020729 noni extract Nutrition 0.000 claims description 59
- 230000005070 ripening Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 238000000855 fermentation Methods 0.000 claims description 22
- 230000004151 fermentation Effects 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 244000057717 Streptococcus lactis Species 0.000 claims description 8
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000021552 granulated sugar Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000002131 composite material Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 230000001965 increasing effect Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 9
- 238000009825 accumulation Methods 0.000 abstract description 6
- 229920002527 Glycogen Polymers 0.000 abstract description 5
- 229940096919 glycogen Drugs 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 244000179886 Moringa oleifera Species 0.000 abstract 1
- 235000011347 Moringa oleifera Nutrition 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 41
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 23
- 230000009182 swimming Effects 0.000 description 16
- 239000004310 lactic acid Substances 0.000 description 15
- 235000014655 lactic acid Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 10
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- IBIPGYWNOBGEMH-DILZHRMZSA-N asperuloside Chemical compound O([C@@H]1OC=C2C(=O)O[C@H]3C=C([C@@H]1[C@H]32)COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBIPGYWNOBGEMH-DILZHRMZSA-N 0.000 description 6
- COUXBBBIXWWAEP-AGUBZPQCSA-N asperuloside Natural products CC(=O)OCC1=C[C@@H]2OC(=O)C3=CO[C@@H](OC[C@H]4O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]4O)[C@H]1[C@H]23 COUXBBBIXWWAEP-AGUBZPQCSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241001133760 Acoelorraphe Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- -1 glycoside compound Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229950007002 phosphocreatine Drugs 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 240000000111 Saccharum officinarum Species 0.000 description 3
- 235000007201 Saccharum officinarum Nutrition 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920002972 Acrylic fiber Polymers 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- ZVXWFPTVHBWJOU-AWQYILTISA-N (1s,4as,5r,7as)-5-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C(C(O)=O)=CO1 ZVXWFPTVHBWJOU-AWQYILTISA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000006549 Arenga pinnata Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- DGDWCRWJRNMRKX-DILZHRMZSA-N Asperulosidic acid Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@@H](O)C=C2COC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGDWCRWJRNMRKX-DILZHRMZSA-N 0.000 description 1
- DGDWCRWJRNMRKX-UHFFFAOYSA-N Asperulosidinsaeure Natural products CC(=O)OCC1=CC(O)C(C(=CO2)C(O)=O)C1C2OC1OC(CO)C(O)C(O)C1O DGDWCRWJRNMRKX-UHFFFAOYSA-N 0.000 description 1
- 244000208235 Borassus flabellifer Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VKWWRUZYBNTDHM-AXECJBQYSA-N Deacetylasperulosidic acid Natural products OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O VKWWRUZYBNTDHM-AXECJBQYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 235000008898 Morinda citrifolia Nutrition 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 244000104275 Phoenix dactylifera Species 0.000 description 1
- 235000010659 Phoenix dactylifera Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- AHFAQKUDQUDLNP-AGUBZPQCSA-N asperulosidic acid Natural products CC(=O)OCC1=C[C@H](O)[C@H]2[C@@H]1[C@H](OC[C@H]3O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]3O)OC=C2C(=O)O AHFAQKUDQUDLNP-AGUBZPQCSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- WBAVLTNIRYDCPM-UHFFFAOYSA-N isoscopolin Natural products COC1=CC=2OC(=O)C=CC=2C=C1OC1OC(CO)C(O)C(O)C1O WBAVLTNIRYDCPM-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 229940100661 nasal inhalant Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- SGTCGCCQZOUMJJ-YMILTQATSA-N scopolin Chemical compound COC1=CC=2C=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SGTCGCCQZOUMJJ-YMILTQATSA-N 0.000 description 1
- SGTCGCCQZOUMJJ-UHFFFAOYSA-N scopolin Natural products COC1=CC=2C=CC(=O)OC=2C=C1OC1OC(CO)C(O)C(O)C1O SGTCGCCQZOUMJJ-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Abstract
本发明涉及作为有效成分包含发酵熟成诺丽、椰子糖或黑砂糖的运动执行能力及疲劳恢复增进用组合物,更具体地,涉及具有增加组织内的糖原储存量和肝功能,提高运动执行能力以及抑制血中疲劳物质的蓄积的效果的用于运动执行能力及疲劳恢复增进的组合物。本发明具有在摄取发酵熟成诺丽及椰子糖复合组合物时,增加组织内的糖原储存量和肝功能,可提高运动持续能力的运动执行能力提高及血中疲劳物质的蓄积的抑制的效果,由此提供运动能力提高及抗疲劳用组合物。本发明的组合物促进疲劳物质的减少,快速进行疲劳恢复或运动能力增强,由此可制备对疲劳恢复及运动能力增强有效的组合物及药学组合物制品。
Description
技术领域
本发明涉及作为有效成分包含发酵熟成诺丽、椰子糖或黑砂糖发酵复合物的组合物,更详细地,涉及具有增加组织内的糖原储存量和肝功能,提高运动执行能力以及抑制血中疲劳物质的蓄积的效果,由此提供用于增进运动执行能力及疲劳恢复的组合物。
背景技术
通常,肌肉在不持续运动时,根据老化,肌肉功能降低,减少肌肉量及肌肉神经接点(neuromuscular junction,motor unit),容易感到疲劳且无力,导致生活的活力减少,生活质量急剧降低。
若感到疲劳的信号,则身体需要可以修养而恢复的时间,但是在忙碌的现代社会上难以正常保持如上疲劳和疲劳恢复的循环。因过劳引起的疲劳的蓄积,稍微不慎诱发慢性疲劳,还可以诱发消化性溃疡、高血压、糖尿病等许多疾病。并且,癌、脑中风、心胀疾病是现代人的主要3大死亡原因,过劳是这些病的主要原因。
疲劳或压力积累的表现是指身心的功能不顺利执行的情况。主要对于疲劳而言,可成为肌肉收缩活动中所需的力不能充分发挥的状态,即运动执行能力减少的状态,与肉体疲劳相反的压力可理解为因精神上的超负荷而导致的身体节奏的不均衡。因此,广义的疲劳是均包括劳累(fatigue)和压力(stress)的概念,可被视为用于肉体或精神活动的能力的减少,具体地,劳累(fatigue)主要是肉体疲劳,其指工作效率降低的状态,以及压力是精神疲劳,其指引起稳态性的混乱的状态。
为了防止这些,持续实施抵抗力运动之类的运动,与此同时,建议一起采取适当的饮食疗法。最近,通过健康热潮,享受生活的悠闲,为了预防和治疗各种成人病,突显运动的重要性。如上所述,为了提高生活质量,需要有规律的运动,不仅是运动选手,普通人也有日常生活中需要更多的能量及持久力的倾向。因此,用于提高身体运动执行能力的补助剂、组合物等的研究长期持续进行,实际上若服用类固醇、咖啡因等化合物,则运动能力增加。但是,这些药物有可能伴随致命的副作用,故而该药物的使用极其受限。
据悉,自然界中存在的植物中大量含有具有防止疾病和抑制老化等生物调节功能的功能性成分,由此正在活跃进行有关天然原材料的研究。最近正在活跃进行利用如植物提取物一样安全性得到保障的天然物来开发功能性补助剂的研究。
对此,本发明人持续进行有关发酵熟成诺丽和椰子糖的研究的结果,确认了通过这些复合物的摄取,增加运动执行能力并抑制血中疲劳因素的蓄积,由此完成了本发明。
现有技术文献
非专利文献
Beck L., 2014, "Coconut sugar: Is it healthier than white sugar, orjust hype?", The Globe&Mail, Retrieved 30 May 2015
Timothy P. E., 2016 Postprandial insulin and glucose levels arereduced in healthy subjects when a standardised breakfast meal issupplemented with a filtered sugarcane molasses concentrate. Eur. J. Nutr.,55(8), 2365-2376
发明内容
本发明的目的在于,解决前述问题及与其相关的其他问题。
本发明人在可有效增进运动执行能力及疲劳恢复的天然成分组合物相关研究中确认包含发酵熟成诺丽、椰子糖或黑砂糖的组合物具有运动执行能力增强及疲劳恢复活性,由此完成了本发明。
本发明的一目的在于,提供作为有效成分包含发酵熟成诺丽、椰子糖及黑砂糖的运动执行能力和/或疲劳恢复增进用组合物。
本发明的另一目的在于,提供包含上述发酵熟成诺丽、椰子糖及黑砂糖的组合物的制备方法。
本发明的另一目的在于,提供运动执行能力和/或疲劳恢复增进用组合物。
本发明的另一目的在于,提供运动执行能力和/或疲劳恢复增进用药学组合物。
本发明的另一目的在于,提供运动执行能力和/或疲劳恢复增进用医药外品组合物。
本发明的另一目的在于,提供运动执行能力和/或疲劳恢复增进用饲料组合物。
要根据本说明书中公开的发明技术思想来实现的技术问题,并不限定于用于解决以上提及的问题的技术问题,本发明的普通技术人员可通过以下的记载明确理解未被提及的另一技术问题。
对其进行具体说明如下。另一方面,本申请中公开的各个说明及实施方式也可适用于各个其他说明及实施方式。即,本申请中公开的多种因素的所有组合属于本申请的范畴中。并且,本申请的范畴不得被视为限定于以下描述的具体说明。
为了解决如上问题,本发明提供运动执行能力及疲劳恢复增进用组合物,上述组合物作为有效成分包含发酵熟成诺丽、椰子糖和/或黑砂糖。
以下,详细说明本发明。
在本发明中,“发酵熟成诺丽”是指在诺丽中接种乳酸菌而发酵及熟成的诺丽。其中,诺丽不受其部位的限制,但是作为一个示例可使用诺丽果。
“发酵诺丽”可以是在诺丽果中接种以下7种乳酸菌中的任一个以上的发酵物:
(1)植物乳杆菌(Lactobacillus plantarum);
(2)副干酪乳杆菌(Lactobacillus paracasei);
(3)鼠李糖乳杆菌(Lactobacillus rhamnosus);
(4)干酪乳杆菌(Lactobacillus casei);
(5)发酵乳杆菌(Lactobacillus fermentum);
(6)罗伊氏乳杆菌 (Lactobacillus reuteri);以及
(7)乳酸乳球菌乳酸亚种(Lactococcus lactis subsp. lactis)。
上述“发酵诺丽”利用生物转化能力优秀的乳酸菌来发酵,其可将作为诺丽中所含的配糖体化合物的东莨菪甙(Scopolin)、车叶草甙(Asperuloside)生物转化为作为非配糖体化合物的东莨菪素(scopoletin)、去乙酰车叶草苷酸(deacetylasperulosidic acid,DAA)及车叶草苷酸(asperulosidic acid)。
在本发明中,上述“发酵诺丽”中生物转化的东莨菪素的含量为100~2000μg/g(以发酵诺丽提取物固体含量60%为基准),去乙酰车叶草苷酸的含量为0.5~15mg/g(以发酵诺丽提取物固体含量60%为基准),车叶草苷酸的含量为0.2~5mg/g(以发酵诺丽提取物固体含量60%为基准)。
在本发明中,“发酵熟成诺丽”也达到与“发酵诺丽”中所含的功能成分东莨菪素、去乙酰车叶草苷酸及车叶草苷酸的含量相同的水准。
本发明的“发酵熟成诺丽”可以是发酵熟成诺丽本身或从中获得的提取物。 作为一例,本发明的发酵熟成诺丽可以是在诺丽果接种乳酸菌而发酵及熟成,并将这些发酵熟成的发酵熟成诺丽榨汁而获得液的提取物。
在本说明书中,“提取物”是指在本领域中通用为粗提取物(Crude extract)的意思,但是在广义上还包含将提取物进一步分馏(Fractionation)的分馏物的意思。即,发酵熟成诺丽提取物,不仅包含利用上述提取溶剂来获得的提取物,还包含在此添加适用精制过程获得的提取物。例如,使上述提取物经由具有规定的分子量截留(cut off)值的超滤膜而获得的分馏、通过基于多种层析(大小、电荷、为了基于疏水性或亲和性的分离而制备的)的分离等添加实施的多种精制方法获得的分馏也包括在本发明的发酵熟成诺丽提取物中。
在本说明书中,“作为有效成分包含”是指包含实现发酵熟成诺丽或其提取物的功效或活性时充分的量。本发明是从作为天然植物材料的发酵熟成诺丽中提取的组合物,由于过量给药也对人体无副作用,因此发酵熟成诺丽提取物包含在本发明的组合物的量的上限可由普通技术人员在适当的范围内选择而实施。
根据本发明的发酵熟成诺丽提取物是利用有机溶剂来提取的,作为提取溶剂可使用的溶剂为如下。
首先,适合作为极性溶剂的有(i)水,(ii)碳原子数为1至6醇(优选地,甲醇、乙醇、丙醇、丁醇、正丙醇、异丙醇、正丁醇、1-戊醇、2-丁氧基乙醇或乙二醇),(iii)乙酸,(iv)二甲基甲酰胺(DMFO,Dimethyl-formamide)及(v)二甲基亚砜(DMSO,Dimethyl sulfoxide)等。
并且,适合作为非极性溶剂的有丙酮、乙腈、乙酸乙酯、乙酸甲酯、氟代烷、戊烷、己烷、2,2,4-三甲基戊烷、癸烷、环己烷、环戊烷、二异丁烯、1-戊烯、1-氯丁烷、1-氯戊烷、o-二甲苯、二异丙基醚、2-氯丙烷、甲苯、1-氯丙烷、氯苯、苯、二乙醚、二乙基硫醚、氯仿、二氯甲烷、1,2-二氯乙烷、苯胺、二乙胺、醚、四氯化碳、二氯甲烷、石油醚及THF等。
作为本发明的提取溶剂的代表性的示例,优选地使用(a)水,(b)碳原子数为1至4的无水或低级醇(甲醇、乙醇、丙醇、丁醇等),(c)上述低级醇和水的混合溶剂,(d)丙酮,(e)乙酸乙酯,(f)氯仿,(g)乙酸丁酯,(h)1,3-丁二醇,(i)己烷及(j)二乙醚等,为了容易的提取,可利用水、乙醇或水和乙醇的混合物来提取。
并且,在本发明中利用的发酵熟成诺丽提取物,通过减压蒸馏及冷冻干燥或喷雾干燥等之类的添加过程,能够以粉末状态制备。
在本发明中,其特征在于,上述发酵熟成诺丽及椰子糖的重量比为70:30至95: 5,更优选的重量比为80:20至90:10。
并且,其特征在于,上述发酵熟成诺丽及黑砂糖的重量比为70:30至95: 5,更优选的重量比为80:20至90:10。
并且,其特征在于,上述发酵熟成诺丽、椰子糖及黑砂糖的重量比为90:5:5至70:15:15,更优选为90:5:5。
根据本发明的一实施方式,本发明涉及包含发酵熟成诺丽、椰子糖和/或黑砂糖的用于增进运动执行能力或疲劳恢复的组合物。
上述组合物能够以粉末、颗粒、片剂、胶囊的形态使用。各剂型的组合物,除了有效成分以外,可根据剂型或使用目的,普通技术人员容易地适当选择相关领域中通常使用的成分来配合,当与其他原料同时适用时,可产生提升效果。
上述组合物在不损害本发明所目的的主要效果的范围内,可包含给主要效果可带来提升效果的其他成分等。例如,为了改善物性,还可包含香料、色素、杀菌剂、抗氧化剂、防腐剂、保湿剂、增粘剂、无机盐类、乳化剂及合成高分子物质等添加剂。
当本发明的组合物使用为健康饮料时,如常规的饮料一样,可包含多种香味剂或天然碳水化合物等作为添加成分。上述的天然碳水化合物为葡萄糖、果糖之类的单糖;麦芽糖、蔗糖之类的二糖;糊精、环糊精之类的多糖;木糖醇、山梨醇、赤藓糖醇等糖醇。作为甜味剂可使用索马甜、甜菊苷提取物之类的天然甜味剂,或者糖精或阿斯巴甜之类的合成甜味剂等。
本发明还提供包含上述发酵熟成诺丽、椰子糖和/或黑砂糖的组合物的制备方法。
根据本发明的一实施方式,本发明提供包含发酵熟成诺丽及椰子糖和/或黑砂糖的组合物的制备方法,其包括:获得利用乳酸菌将诺丽进行发酵和/或熟成的发酵熟成诺丽的步骤;以及在上述发酵熟成诺丽添加椰子糖和/或黑砂糖而熟成的步骤。
在本发明中,提供包含发酵熟成诺丽、椰子糖和/或黑砂糖的组合物的制备方法,上述方法包括:步骤(a),在诺丽果接种乳酸菌,发酵及熟成,制备发酵熟成诺丽;步骤(b),将上述发酵熟成诺丽榨汁;以及步骤(c),在上述发酵熟成诺丽添加椰子糖和/或黑砂糖而混合。
在本发明中,制备方法还可包括步骤(d),该步骤(d)在上述步骤(c)中在发酵熟成诺丽混合椰子糖和/或黑砂糖之后,添加熟成。
在本发明中,上述发酵及熟成并不限定于此,在35至40℃下可进行48至168小时。
以将发酵过程中生成的发酵液撒布于发酵物的上部的方式实施上述熟成,该熟成实施1天至3天,更具体地每2天实施。
在本发明中,将椰子(椰子树)、棕榈树, 枣椰树、尼巴棕榈叶, 桄榔树等棕榈科所属的椰子树的树液熬制而得的糖叫做棕榈糖或香椰糖(palm sugar),椰子糖(或别称椰子糖)是指由椰子(coconut palm)的花蕾茎的树液生产的香椰糖,其为商业上也能入手的物质。
椰子糖的主要结构成分,包含蔗糖(sucrose)70~79%、葡萄糖(glucose)及果糖(fructose)各自为3~9%(Beck L., 2014, "Coconut sugar: Is it healthier thanwhite sugar, or just hype?", The Globe&Mail, Retrieved 30 May 2015)。
黑砂糖(Muscovado)是将甘蔗榨汁液(汁)熬制而形成糖蜜的、未精制的糖,即干燥为深褐色的颗粒之后被粉碎而制备的糖,其指从磷酸、甲酸、二氧化硫、防腐剂或精制的糖中使用的漂白剂或粘性改性剂之类的化学物质中完全自由的糖。相比于加工的白糖或红糖,糖蜜含量高,香味浓,颜色偏深。是商业上也能入手的物质。
根据本发明的一实施方式,本发明涉及包含发酵熟成诺丽、椰子糖和/或黑砂糖的用于增进运动执行能力或疲劳恢复的药学组合物。
根据本发明的药学组合物,单独包含有效成分或者能够以适合的形态一起剂型化药学上允许的载体,并可添加包含赋形剂或稀释剂。上述“药学上允许的”在生理学上允许并给药到人体时,通常是指不引起胃肠障碍、眩晕症等之类的过敏反应或与其类似的反应的非毒性的组合物。
作为药学上允许的载体,例如可添加包含口服用载体或非口服用载体。口服用载体可包含乳糖、淀粉纤维素衍生物、硬脂酸镁、硬脂酸等。而且,可包含针对肽制剂的使用为口服用的多种药物传递物质。并且,非口服用载体可包含水、适合的油、生理盐水、水性葡萄糖及乙二醇等,并可添加包含稳定剂及保存剂。作为适合的稳定剂有亚硫酸氢钠、亚硫酸钠或抗坏血酸之类的抗氧化剂。适合的保存剂有氯化苯甲烃铵、尼泊金甲酯或尼泊金丙酯及氯丁醇。本发明的药学组合物,除了上述成分以外可添加包含润滑剂、湿润剂、甜味剂、香味剂、乳化剂、悬浮剂等。另外药学上允许的载体及制剂可参照以下文献中记载的内容(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company,Easton, PA, 1995)。
本发明的组合物,通过任何方法都能给药到包括人在内的哺乳动物中。例如,能够口服或非口服给药。非口服给药方法不限定于此,但是可以是静脉内、肌肉内、动脉内、骨髓内、硬膜内、心脏内、经皮、皮下、腹腔内、鼻腔内、肠管、局部或舌下或直肠内给药。
本发明的药学组合物根据如上所述的给药途径可剂型化为口服用或非口服用制剂。
就口服用制剂而言,本发明的组合物可利用本领域公知的方法剂型化为粉末、颗粒、片剂、丸剂、糖衣片剂、胶囊剂、液剂、凝胶剂、糖浆剂、浆料剂、悬浮液等。例如,口服用制剂,将活性成分与固体赋形剂配合之后将其粉碎,添加适合的补助剂之后,加工为颗粒混合物,由此可获得片剂或糖衣片剂。作为适合的赋形剂的例,可包含包含乳糖、葡萄糖、蔗糖、山梨糖醇、甘露醇、木糖醇、赤藓糖醇及麦芽糖醇等的糖类、包含玉米淀粉、麦淀粉、米淀粉及土豆淀粉等的淀粉类、包含纤维素、甲基纤维素、羧甲基纤维素钠及羟丙基甲基-纤维素等的纤维素类、明胶、聚乙烯吡咯烷酮等之类的填充剂。并且,根据情况,可添加作为崩解剂的交联聚乙烯吡咯烷酮、琼脂、海藻酸或海藻酸钠等。进而,本发明的药学组合物还可包含抗凝集剂、润滑剂、湿润剂、香料、乳化剂及防腐剂等。
对于非口服用制剂而言,通过本领域的公知的方法,能够以注射剂、膏化剂、乳液剂、外用软膏剂、油剂、保湿剂、凝胶剂、气溶胶及鼻腔吸入剂的形态进行剂型化。这些剂型记载于所有制药化学中通常公知的处方文献(Remington's Pharmaceutical Science,19th ed., Mack Publishing Company, Easton, PA,1995)。
本发明的组合物的总有效量,能够以单剂量(single dose)给药到患者,并可通过以多剂量(multiple dose)长期给药的分次治疗方法(fractionated treatmentprotocol)给药。本发明的药学组合物,可根据疾病的程度来改变有效成分的含量。优选地,对于本发明的药学组合物的优选的整体容量而言,按患者体重每1㎏,每天可以是约0.01㎍至10000mg,优选地可以是0.1㎍至500mg,最优选地可以是100mg至500mg。但是,上述药学组合物的容量,不仅考虑制剂化方法、给药途径及治疗次数,而且也考虑患者的年龄、体重、健康状态、性别、疾病的重症度、饮食及排泄率等多种因素来确定有关患者的有效剂量,因此当考虑到这个问题时,只要是本技术领域的普通技术人员就能确定本发明的组合物的适当的有效剂量。根据本发明的药学组合物,只要呈现本发明的效果,其剂型、给药途径及给药方法就不受特殊限制。
根据本发明的一实施方式,本发明涉及包含发酵熟成诺丽、椰子糖和/或黑砂糖的用于增进运动执行能力或疲劳恢复的医药外品组合物。
本发明中使用的术语“医药外品”是指出于诊断、治疗、减轻或预防人或动物的疾病的目的来使用的物品中除了不是器具、机械或装置的物品以及出于给人或动物的结构和功能带来药理学影响的目的使用的物品中除了不是器具、机械或装置的物品,作为一个具体例,可包含内服用制剂,但并不限定于此,医药外品的制剂化方法、容量、利用方法、结构成分等可从技术领域中公知的常规技术中适当选择。
本发明的医药外品组合物,除了上述成分以外,根据需要还可包含药学上允许的载体、赋形剂或稀释剂。上述药学上允许的载体、赋形剂或稀释剂,只要不损害本发明的效果,就不受限制,例如,可包含填充剂、增量剂、结合剂、湿润剂、崩解剂、表面活性剂、润滑剂、甜味剂、芳香剂、保存剂等。
根据本发明的一实施方式,本发明涉及包含发酵熟成诺丽、椰子糖和/或黑砂糖的用于增进运动执行能力或疲劳恢复的饲料组合物。
在本发明中,上述饲料组合物,能够以常规的饲料形态进行剂型化,并可一同包含公知的饲料成分。并且,还可以使用为所用到的饲料中以添加剂形态添加的饲料添加剂。本发明的饲料添加剂相当于饲料管理法上的补助饲料,还可包含碳酸氢钠(重碳酸钠)、膨润土(bentonite)、氧化镁、复合矿物质等矿物质制剂,作为锌、铜、钴、硒等微量矿物质的矿物制剂,胡萝卜素、维生素E、维生素A、D、E、烟酸、维生素B复合体等维生素制剂,蛋氨酸、赖氨酸等氨基酸保护剂,脂肪酸钙盐等脂肪酸保护剂,益生菌(乳酸菌制剂)、酵母培养物、霉菌发酵物等益生菌、酵母剂等。
本发明的饲料或饲料添加剂可适用于包括哺乳类、家禽及鱼类的多个动物饲料。
根据本发明的运动执行能力及疲劳恢复增进用复合组合物中包含的发酵熟成诺丽和椰子糖或黑砂糖复合组合物,具有运动执行能力及疲劳恢复增进效果。并且,上述发酵熟成诺丽,产生在诺丽果的发酵工程中可提高消化吸收的效果,促进消化力相对差的成人、老人的消化力,并促进排便活动,另一方面,由于是天然原料,因此无毒性和副作用,由此具有可放心摄取的效果。
并且,上述发酵熟成诺丽的制备工程,可大幅节减制备成本,由此具有大幅减少消费者的购买费用负担的效果。
并且,发酵熟成诺丽和椰子糖或黑砂糖复合组合物是相比于以往诺丽,喜好度功能性得到改善,由此消费者无负担地享受的组合物。
附图说明
图1为摄取本发明的对照组(control)、单一组及复合组合物之后,强迫游泳之后测定运动执行时间的结果图表。
图2为摄取本发明的对照组(control)、单一组及复合组合物之后,强迫游泳之后测定所变化的血中乳酸的浓度的结果图表。
图3为摄取本发明的对照组(control)、单一组及复合组合物之后,测定强迫游泳之后测定无机磷酸盐的结果图表。
图4为摄取本发明的对照组(control)、单一组及复合组合物之后,强迫游泳之后测定肌酸激酶(Creatine kinase)浓度的结果图表。
图5表示非精炼糖和黑砂糖的结晶及功能(形态)等的差异。
具体实施方式
以下,通过以下实施例更详细说明本发明。但是,这些实施例用于例示说明本发明,本发明的范围并不仅限定于这些实施例。
运动执行能力及疲劳恢复增进用组合物通过如下过程制备。
实施例1:本发明的运动执行能力及疲劳恢复增进用组合物的制备
1.1:发酵熟成诺丽的制备
在诺丽果690kg接种复合乳酸菌(7种复合乳酸菌AON1805,(株)乐土美森),在37℃下发酵45天以上。从发酵起始日起,每7天接收10L发酵液,移至诺丽果上侧并撒布,实施发酵及熟成。此时,使用的复合乳酸菌(7种复合乳酸菌AON1805,(株)乐土美森)的组成如以下表1所示。
熟成结束之后,将上述发酵熟成诺丽榨汁,去除固体,获得发酵熟成诺丽提取物。
[表1]
1.2:椰子糖的制备
从椰子树的花茎中采集汁之后,通过传统方式,在90℃下加热并摇匀,将上述椰子花茎汁浓缩至蜂蜜茶形态之后使其固化,将完全固化的花汁液细磨,由此制备天然椰子糖。
1.3:黑砂糖(Muscovado)的制备
去除收获的甘蔗的叶子和杂质,将从甘蔗中榨出的汁放入到大锅,熬到充分时间之后,去除浮上的杂质和沉淀物,若处于水分蒸发的状态,则均匀打翻至成为粉末状态为止,干燥之后,均匀粉碎,由此制备黑砂糖。
1.4:利用发酵熟成诺丽提取物及椰子糖的复合物的制备
以通过上述1.1至1.3制备的发酵熟成诺丽提取物、椰子糖的不同配合比混合之后,熟成15天,制备复合物。
[复合物的制备]
复合物1:发酵熟成诺丽提取物(重量百分比)90:椰子糖(重量百分比)10
复合物2:发酵熟成诺丽提取物(重量百分比)80:椰子糖(重量百分比)20
复合物3:发酵熟成诺丽提取物(重量百分比)70:椰子糖(重量百分比)30
1.5:利用发酵熟成诺丽提取物及黑砂糖的复合物的制备
以通过上述1.1至1.3制备的发酵熟成诺丽提取物、黑砂糖的不同配合比混合之后,熟成15天,制备复合物。
[复合物的制备]
复合物4:发酵熟成诺丽提取物(重量百分比)90:黑砂糖(重量百分比)10
复合物5:发酵熟成诺丽提取物(重量百分比)80:黑砂糖(重量百分比)20
复合物6:发酵熟成诺丽提取物(重量百分比)70:黑砂糖(重量百分比)30
1.6:利用发酵熟成诺丽提取物、椰子糖及黑砂糖的复合物的制备
以通过上述1.1至1.3制备的发酵熟成诺丽提取物、椰子糖及黑砂糖的不同配合比混合之后,熟成15天,制备复合物。
[复合物的制备]
复合物7:发酵熟成诺丽提取物(重量百分比)90:椰子糖(重量百分比) 5:黑砂糖(重量百分比)5
复合物8:发酵熟成诺丽提取物(重量百分比)80:椰子糖(重量百分比)10:黑砂糖(重量百分比)10
复合物9:发酵熟成诺丽提取物(重量百分比)70:椰子糖(重量百分比)15:黑砂糖(重量百分比)15
1.7:利用发酵熟成诺丽提取物、食糖的复合物的制备
以通过上述1.1制备的发酵熟成诺丽提取物、非精炼糖的不同配合比混合之后,熟成15天,制备复合物。
[复合物的制备]
复合物10:发酵熟成诺丽提取物(重量百分比)90:非精炼糖(重量百分比)10
实验例1:运动执行能力增进试验
确认通过上述实施例1.1至1.3制备的单一提取物和通过实施例1.4至1.6制备的复合物的运动执行能力增进效果。
(1)诱发小白鼠的疲劳
分发上述体重30g的ICR系小白鼠(奥源生物,韩国),在20℃至24℃的温度条件及55%的湿度条件下,以明暗周期为12小时(light/dark cycle)适应1周之后,将实验动物如下分类为各个8只的实验组。设置为实验组1(非运动组,由以下Normal表示)、实验组2(运动对照组,由以下Control表示)、实验组3(发酵熟成诺丽100mg/kg给药组,由以下FN表示)、实验组4(椰子糖100mg/kg给药组,由以下CS表示)、实验组5(黑砂糖100mg/kg给药组,由以下MS表示)、实验组6(复合物10 100mg/kg给药组,由以下FNS表示)、实验组7(复合物1 100mg/kg给药组,由以下C 1表示)、实验组8(复合物2 100mg/kg给药组,由以下C 2表示)、实验组9(复合物3 100mg/kg给药组,由以下C 3表示)、实验组10(复合物4 100mg/kg给药组,由以下C 4表示)、实验组11(复合物5 100mg/kg给药组,由以下C 5表示)、实验组12(复合物6100mg/kg给药组,由以下C 6表示)、实验组13(复合物7 100mg/kg给药组,由以下C 7表示)、实验组14(复合物8 100mg/kg给药组,由以下C 8表示)、实验组15(复合物9 100mg/kg给药组,由以下C 9表示),试验物质按1次/1天总共给药4周。
(2)复合物的运动执行能力测定
实验动物从实验开始16小时之前起,以稳定的状态保持饲养条件之后,在丙烯酸塑料水槽(70cm×70cm×60cm)内放入约70%左右的水,在水槽中游泳。游泳时间将实验动物虚脱而不再活动的状态设定为终点,将开始时间至结束时间未知的时间测定为游泳时间。
其结果,如图1所示,为了测定运动执行能力,测定至虚脱时为止的游泳时间。实验结果,确认到在相同的浓度条件下以对照组为基准,处理本发明的组合物的所有组中,游泳时间相比于单一组(发酵诺丽、椰子糖及黑砂糖给药组)增加,组合物摄取的运动执行能力相比于单一组摄取增进,尤其,在复合物1、4及7给药组中,游泳时间为1081至1119秒且最高,由此可确认运动执行能力优秀。
另一方面,发酵熟成诺丽提取物和作为非精炼糖复合物的FNS组的游泳时间为913,呈现相比于复合物1、4及7给药组显著低的结果。
这些结果呈现如下:比起基于糖的糖分供应的运动执行能力的增加,基于椰子糖及黑砂糖和发酵熟成诺丽复合物的运动执行能力的提高结果更优秀。
本发明的组合物,在行动实验结果显示,移动距离及运动时间可增加,并可呈现运动能力增强。并且,上述组合物可增加血葡萄糖的浓度,可增加肌肉内的糖原(glycogen)浓度,并可减少乳酸脱氢酶(LDH,lactate dehydrogenase)浓度。
实验例2:疲劳恢复增进试验
(1)乳酸含量测定
根据上述实验例1进行实验之后,将给药结束日饲养的小白鼠作为对象,实施强迫游泳试验,测定作为代表性的疲劳物质的血中乳酸生成。
实验动物从实验开始16小时之前起,以稳定的状态保持饲养条件之后,在丙烯酸塑料水槽(70cm×70cm×60cm)内放入约70%左右的水,在水槽中游泳。游泳时间为15分钟,同样适用在所有实验动物。游泳结束后,为了测定有氧运动后的肌肉疲劳度,在休息期,按10分钟单位,从尾部采血,利用乳酸测定仪(Lactate Pro LT-1710, ARKRAY Inc. /JAPAN)测定血清乳酸含量。
其结果显示,游泳后乳酸的浓度比起稳定期增加6.5倍以上,相比于对照组、发酵熟成诺丽、椰子糖及黑砂糖单独给药组,组合物组在相同浓度条件下显著减少血中乳酸含量。尤其,在相同浓度条件下,本发明的组合物的试验组,相比于对照组(control),呈现4%至55%的低乳酸浓度,由此可确认到显著减少作为肌肉疲劳度产生物质的乳酸。
尤其,作为发酵熟成诺丽提取物和非精炼糖复合物的FNS组的乳酸浓度为4.34水准,相比于复合物1(C 1)、4(C 4)及7(C 7)给药组,调查为显著高的水准的浓度。
由此,本发明的组合物促进疲劳恢复,由此确认提高运动能力的功效突出。
(2)游泳疲劳后血液化学检查
根据上述实验例1进行实验之后,将给药结束日饲养的小白鼠作为对象,实施强迫游泳试验之后,小白鼠牺牲之后,将从心脏中采血之后分离的血清委托给绿十字研究所,利用自动分析仪,测定血中无机磷(Inorganic phosphorus)浓度、肌酸激酶(Creatinekinase,CK)浓度。
运动中,肌肉通过重复的肌肉收缩,提高肌球蛋白(myosin)和肌动蛋白(actin)的亲和力的步骤中,ATP水解,因此急剧增加血中无机磷浓度。运动中,若血清无机磷浓度急剧增加,则肌纤维的交联桥(cross-bridge)弱化,由此能量产生降低。由此,血中的无机磷的浓度用作对于肌肉的疲劳度重要的指标。
确认结果,血清中无机磷的浓度,相比于运动对照组(control),无机磷的浓度在复合物给药组中均显著减少。在复合物1、4及7给药组中,分别以11.01mg/dL、11.18 mg/dL、11.07 mg/dL呈现最低的值,减少作为疲劳度因素的无机磷酸盐含量,由此可确认对疲劳恢复有效。
但是,发酵熟成诺丽提取物和糖的复合物(FNS)也以12.58mg/dL浓度,在运动对照组(control)中呈现具有显著性的减少,但是呈现与发酵熟成诺丽单一给药组类似的水准的无机磷浓度。
另一方面,与复合物1、4及7给药组相比时,调查为高水准的无机磷浓度。
肌酸激酶(Creatine kinase)是EC 2.7. 3.2. 1943年K. Lohmans从骨骼肌中发现的酶,其为将生成由肌酸和ATP形成磷酸肌酸的反应催化的酶,用于催化磷酸肌酸+ADP肌酸+ATP的的罗曼氏反应(将高能量磷酸基从磷酸肌酸转移至ADP,合成ATP的反应)。肌肉中多而骨骼肌收缩时,大量消耗ATP的情况下,生成肌肉中大量存在的磷酸肌酸中获得的ATP而供应。
试验结果,运动对照组(control)的肌酸激酶(Creatine kinase)调查为562 IU/L数值,单一组及复合物给药组中相比于运动对照组,均调查为高数值。
尤其,复合物1(C 1)、复合物4(C 4)及复合物7(C 7)给药组分别为967 IU/L、955IU/L及966 IU/L,呈现最高数值,在相同浓度条件下促进ATP再合成,由此可确认对肌肉疲劳度减轻有效。
如复合物1、4及7给药组一样,对于添加作为糖类成分的糖的发酵熟成诺丽和非精炼糖复合物FNS给药组而言,调查到肌酸激酶(Creatine kinase)的浓度数值(709 IU.L)显著低。
由以上的说明应当可理解本发明所属技术领域的普通技术人员在不变更技术思想或必需特征的情况下能够将本发明实施为其他具体方式。与此相关的是,应当要理解以上描述的实施例在整体方面上是示例性的,而不是限定性的。本发明的范围比起上述详细的说明,应当要理解所附的权利要求书的意思及范围及其等同概念中导出的所有变更或变形的方式包括在本发明的范围内。
Claims (10)
1.一种用于增进运动执行能力或疲劳恢复的发酵诺丽组合物,其特征在于,作为有效成分包含:
(1)重量比为90:10的发酵熟成诺丽提取物及椰子糖,或者
(2)重量比为90:10的发酵熟成诺丽提取物及黑砂糖,或者
(3)重量比为90:5:5的发酵熟成诺丽提取物、椰子糖及黑砂糖;
其中,所述发酵熟成诺丽提取物是通过以下方法制备的:将诺丽接种复合乳酸菌,在37℃下发酵45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体,所述复合乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;并且
其中,按照上述(1)的比例将所述发酵熟成诺丽提取物与椰子糖混合,或者按照上述(2)的比例将所述发酵熟成诺丽提取物与黑砂糖混合,按照上述(3)的比例将所述发酵熟成诺丽提取物与椰子糖及黑砂糖混合,然后熟成15天,制备得到所述发酵诺丽组合物。
2.根据权利要求1所述的发酵诺丽组合物,其特征在于,所述组合物为选自粉末、颗粒、丸、片剂、胶囊、糖浆中的任一种剂型。
3.一种用于增进运动执行能力或疲劳恢复的发酵诺丽药学组合物,其特征在于,作为有效成分包含:
(1)重量比为90:10的发酵熟成诺丽提取物及椰子糖,或者
(2)重量比为90:10的发酵熟成诺丽提取物及黑砂糖,或者
(3)重量比为90:5:5的发酵熟成诺丽提取物、椰子糖及黑砂糖;
其中,所述发酵熟成诺丽提取物是通过以下方法制备的:将诺丽接种复合乳酸菌,在37℃下发酵45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体,所述复合乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;并且
其中,按照上述(1)的比例将所述发酵熟成诺丽提取物与椰子糖混合,或者按照上述(2)的比例将所述发酵熟成诺丽提取物与黑砂糖混合,按照上述(3)的比例将所述发酵熟成诺丽提取物与椰子糖及黑砂糖混合,然后熟成15天,制备得到所述组合物。
4.一种用于增进运动执行能力或疲劳恢复的发酵诺丽医药外品组合物,其特征在于,作为有效成分包含:
(1)重量比为90:10的发酵熟成诺丽提取物及椰子糖,或者
(2)重量比为90:10的发酵熟成诺丽提取物及黑砂糖,或者
(3)重量比为90:5:5的发酵熟成诺丽提取物、椰子糖及黑砂糖;
其中,所述发酵熟成诺丽提取物是通过以下方法制备的:将诺丽接种复合乳酸菌,在37℃下发酵45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体,所述复合乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;并且
其中,按照上述(1)的比例将所述发酵熟成诺丽提取物与椰子糖混合,或者按照上述(2)的比例将所述发酵熟成诺丽提取物与黑砂糖混合,按照上述(3)的比例将所述发酵熟成诺丽提取物与椰子糖及黑砂糖混合,然后熟成15天,制备得到所述组合物。
5.一种用于增进运动执行能力或疲劳恢复的发酵诺丽饲料组合物,其特征在于,作为有效成分包含:
(1)重量比为90:10的发酵熟成诺丽提取物及椰子糖,或者
(2)重量比为90:10的发酵熟成诺丽提取物及黑砂糖,或者
(3)重量比为90:5:5的发酵熟成诺丽提取物、椰子糖及黑砂糖;
其中,所述发酵熟成诺丽提取物是通过以下方法制备的:将诺丽接种复合乳酸菌,在37℃下发酵45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体,所述复合乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;并且
其中,按照上述(1)的比例将所述发酵熟成诺丽提取物与椰子糖混合,或者按照上述(2)的比例将所述发酵熟成诺丽提取物与黑砂糖混合,按照上述(3)的比例将所述发酵熟成诺丽提取物与椰子糖及黑砂糖混合,然后熟成15天,制备得到所述组合物。
6.一种包含发酵熟成诺丽提取物及椰子糖的组合物的制备方法,其特征在于,包括:步骤(a),利用乳酸菌将诺丽在37℃进行发酵及熟成45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体而获得发酵熟成诺丽,所述乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;以及步骤(b),在所述发酵熟成诺丽添加椰子糖,所述发酵熟成诺丽提取物与所述椰子糖的重量比为90:10,随后熟成15天。
7.一种包含发酵熟成诺丽提取物及黑砂糖的组合物的制备方法,其特征在于,包括:步骤(a),利用乳酸菌将诺丽在37℃进行发酵及熟成45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体而获得发酵熟成诺丽,所述乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;以及步骤(b),在所述发酵熟成诺丽添加黑砂糖,所述发酵熟成诺丽提取物与所述黑砂糖的重量比为90:10,随后熟成15天。
8.一种包含发酵熟成诺丽、椰子糖及黑砂糖的组合物的制备方法,其特征在于,包括:步骤(a),利用乳酸菌将诺丽在37℃进行发酵及熟成45天以上,从发酵起始日起,每7天接收发酵液,移至诺丽果上侧并撒布,实施发酵及熟成,将产物榨汁去除固体而获得发酵成熟诺丽,所述乳酸菌为70%的植物乳杆菌Lactobacillus plantarum、5%的鼠李糖乳杆菌Lactobacillus rhamnosus、5%的干酪乳杆菌Lactobacillus casei、5%的发酵乳杆菌Lactobacillus fermentum、5%的副干酪乳杆菌Lactobacillus paracasei、5%的罗伊氏乳杆菌Lactobacillus reuteri、5%的乳酸乳球菌乳酸亚种Lactobacillus lactis subsp. lactis;以及步骤(b),在所述发酵熟成诺丽添加椰子糖及黑砂糖,所述发酵熟成诺丽提取物与所述椰子糖及所述黑砂糖的重量比为90:5:5,随后熟成15天。
9.一种发酵诺丽组合物,其特征在于,通过根据权利要求7或8所述的方法获得。
10.根据权利要求9所述的发酵诺丽组合物,其特征在于,所述组合物具有增进运动执行能力或疲劳恢复的能力。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200185594 | 2020-12-29 | ||
KR10-2020-0185594 | 2020-12-29 | ||
KR1020210163434A KR102624965B1 (ko) | 2020-12-29 | 2021-11-24 | 발효숙성노니, 코코넛 슈가 또는 모스코바도 슈가를 유효성분으로 포함하는 운동수행능력 및 피로회복 증진용 조성물 |
KR10-2021-0163434 | 2021-11-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114680215A CN114680215A (zh) | 2022-07-01 |
CN114680215B true CN114680215B (zh) | 2024-03-12 |
Family
ID=82137131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111627646.9A Active CN114680215B (zh) | 2020-12-29 | 2021-12-28 | 作为有效成分包含发酵熟成诺丽、椰子糖或黑砂糖的运动执行能力及疲劳恢复增进用组合物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20220211793A1 (zh) |
CN (1) | CN114680215B (zh) |
TW (1) | TW202228754A (zh) |
WO (1) | WO2022145892A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791139A (zh) * | 2010-02-01 | 2010-08-04 | 阚欢 | 一种基于诺丽果发酵汁降血糖或血压的液体组合物及制备方法 |
CN102131401A (zh) * | 2008-08-21 | 2011-07-20 | 雀巢产品技术援助有限公司 | 复合甜食及其制备方法 |
CN103596451A (zh) * | 2011-06-07 | 2014-02-19 | 不二制油株式会社 | 大豆乳化组合物在含有来自大豆原料的饮食品中的新用途 |
CN108271975A (zh) * | 2018-01-18 | 2018-07-13 | 深圳中科荣耀生物科技有限公司 | 一种抗疲劳的诺丽果发酵液复合果汁及其制备方法 |
KR20200040205A (ko) * | 2018-10-08 | 2020-04-17 | 박은영 | 발효숙성 노니와 코코넛 슈가를 포함하는 발효 노니 식초, 이를 포함하는 식초음료 및 이의 제조방법 |
KR20200077374A (ko) * | 2018-12-19 | 2020-06-30 | (주)애터미오롯 | 노니 주스의 이취억제 및 유효성분이 강화된 발효농축액 및 그 제조방법 |
KR102151371B1 (ko) * | 2020-03-02 | 2020-09-02 | 박은영 | 발효 노니를 포함하는 당뇨 예방 및 개선용 식품 조성물 및 그 제조방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100574236B1 (ko) * | 2003-11-22 | 2006-04-26 | 황재복 | 노니열매를 이용한 노니액기스 제조방법 |
CN101057700B (zh) * | 2007-04-17 | 2010-07-21 | 海南万维生物制药技术有限公司 | Noni发酵果汁的加工方法及Noni发酵果汁 |
KR20090072555A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 노니원 | 노니열매의 농축액 제조방법 |
KR102151372B1 (ko) * | 2020-03-02 | 2020-09-02 | 박은영 | 발효 노니를 포함하는 남성 갱년기 증후군 예방 및 개선용 식품 조성물 및 그 제조방법 |
-
2021
- 2021-12-24 WO PCT/KR2021/019831 patent/WO2022145892A1/ko active Application Filing
- 2021-12-28 TW TW110149148A patent/TW202228754A/zh unknown
- 2021-12-28 CN CN202111627646.9A patent/CN114680215B/zh active Active
- 2021-12-29 US US17/646,464 patent/US20220211793A1/en active Pending
-
2023
- 2023-02-27 US US18/175,099 patent/US20230218699A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102131401A (zh) * | 2008-08-21 | 2011-07-20 | 雀巢产品技术援助有限公司 | 复合甜食及其制备方法 |
CN101791139A (zh) * | 2010-02-01 | 2010-08-04 | 阚欢 | 一种基于诺丽果发酵汁降血糖或血压的液体组合物及制备方法 |
CN103596451A (zh) * | 2011-06-07 | 2014-02-19 | 不二制油株式会社 | 大豆乳化组合物在含有来自大豆原料的饮食品中的新用途 |
CN108271975A (zh) * | 2018-01-18 | 2018-07-13 | 深圳中科荣耀生物科技有限公司 | 一种抗疲劳的诺丽果发酵液复合果汁及其制备方法 |
KR20200040205A (ko) * | 2018-10-08 | 2020-04-17 | 박은영 | 발효숙성 노니와 코코넛 슈가를 포함하는 발효 노니 식초, 이를 포함하는 식초음료 및 이의 제조방법 |
KR20200077374A (ko) * | 2018-12-19 | 2020-06-30 | (주)애터미오롯 | 노니 주스의 이취억제 및 유효성분이 강화된 발효농축액 및 그 제조방법 |
KR102151371B1 (ko) * | 2020-03-02 | 2020-09-02 | 박은영 | 발효 노니를 포함하는 당뇨 예방 및 개선용 식품 조성물 및 그 제조방법 |
Non-Patent Citations (6)
Title |
---|
Evaluation of the Ergogenic Potential of Noni Juice;De-lu Ma et al;《PHYTOTHERAPY RESEARCH》;第21卷(第11期);第1100-1101页 * |
北京中医药大学营养教研室编.《现代家庭药膳疾病防治药膳》.新华出版社,2003,第184页. * |
周兆祥著.《极简蔬果汁》.河北科学技术出版社,2020,第243-244页. * |
孟宪军等主编.《功能食品》.中国农业大学出版社,2017,第125-126页. * |
王增编著.《黑色食品食疗法》.中国妇女出版社,2006,第322页. * |
钟秀华著.《家常汤饮》.广东人民出版社,2010,第131页. * |
Also Published As
Publication number | Publication date |
---|---|
TW202228754A (zh) | 2022-08-01 |
WO2022145892A1 (ko) | 2022-07-07 |
US20230218699A1 (en) | 2023-07-13 |
CN114680215A (zh) | 2022-07-01 |
US20220211793A1 (en) | 2022-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100510239B1 (ko) | 옥수수 수염과 식이섬유를 함유하는 조성물의 제조방법 | |
JP4669920B2 (ja) | 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材 | |
KR101930483B1 (ko) | 발효 청미래덩굴 잎 및 이의 추출물 | |
US10898535B2 (en) | Composition for inhibiting and preventing myopathy, containing bean leaf extract as active ingredient | |
US20230248796A1 (en) | Composition for stress relief containing fermented ripened noni and calamansi extract as active ingredients | |
CN101707910A (zh) | 具有交感神经活动亢进作用的医药组合物或饮食物 | |
KR101261029B1 (ko) | 칠면초를 포함하는 당뇨병 예방 또는 개선용 조성물 | |
CN114680215B (zh) | 作为有效成分包含发酵熟成诺丽、椰子糖或黑砂糖的运动执行能力及疲劳恢复增进用组合物 | |
WO2012140894A1 (ja) | 医薬用組成物 | |
US20070053929A1 (en) | Marine algae extract and lipase inhibitor containing the same | |
KR100601191B1 (ko) | 혈당 강하제 | |
KR102235563B1 (ko) | 고함량 아르기닌을 포함하는 피로회복 및 성기능 개선용 조성물 | |
KR102624965B1 (ko) | 발효숙성노니, 코코넛 슈가 또는 모스코바도 슈가를 유효성분으로 포함하는 운동수행능력 및 피로회복 증진용 조성물 | |
KR20150015305A (ko) | 주박 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
KR102320221B1 (ko) | 쥐오줌풀 추출물을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물 | |
KR0137897B1 (ko) | 두충엽을 주원료로 함유한 건강식품 조성물 | |
KR20200039607A (ko) | 고구마 줄기를 포함하는 장내 미생물 개선용 조성물 | |
KR20150031373A (ko) | 비타민나무 잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학 조성물 및 식품 조성물 | |
KR100887234B1 (ko) | 상황버섯 추출물을 포함하는 당뇨병 합병증 치료 또는예방용 조성물 | |
KR20170122612A (ko) | 호로파 추출물 및 페룰산을 함유하는 스포츠용 조성물 및 이의 제조방법 | |
KR101649830B1 (ko) | 방사무늬김 추출물을 함유하는 당뇨병의 예방 또는 치료용 조성물 | |
US20200360455A1 (en) | Composition for improving physical strength or athletic ability, containing nutmeg extract as active ingredient | |
KR101818320B1 (ko) | 잣버섯 추출물을 유효성분으로 하는 알코올성 지방간 개선, 치료 또는 예방용 조성물 | |
KR20150091771A (ko) | 바다포도 추출물을 포함하는 당뇨병 치료 또는 예방용 조성물 | |
KR101026857B1 (ko) | 비파 추출물을 함유하는 당뇨병 예방 또는 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |